A compartmental epidemiological model for the dissemination of the COVID-19 disease

Evangelos Matsinos

Abstract

A compartmental epidemiological model with seven groups is introduced herein, to account for the dissemination of diseases similar to the Coronavirus disease 2019 (COVID-19). In its simplified version, the model contains ten parameters, four of which relate to characteristics of the virus, whereas another four are transition probabilities between the groups; the last two parameters enable the empirical modelling of the effective transmissibility, associated in this study with the cumulative number of fatalities due to the disease within one country. The application of the model to the fatality data (the main input herein) of five countries (to be specific, of those which had suffered most fatalities by April 30, 2020) enabled the extraction of an estimate for the basic reproduction number $R_0$ for the COVID-19 disease: $R_0 = 4.91(34)$.

Key words: Epidemiology, infectious disease, compartmental model, mathematical modelling and optimisation, COVID-19, SARS-CoV-2

1 Introduction

The dissemination of the Coronavirus disease 2019 (COVID-19), an infectious disease caused by the ‘Severe Acute Respiratory Syndrome Coronavirus 2’ pathogen (SARS-CoV-2), has become a major global concern; on March 11, 2020, the World Health Organisation (WHO) declared a pandemic. At the time this work is publicised, no formal treatment or vaccine exist; to alleviate the suffering in the severe and critical cases, a number of empirical treatments are applied, and medicines, which had been developed against other diseases, are administered. The onset of symptoms (fever, cough, difficulty in breathing) occurs within a few days of the exposure. The (mild) first phase of the disease is frequently followed by a more problematic second phase, when complications (pneumonia, acute respiratory distress syndrome, kidney failure, etc.) arise and may prove life-threatening for the infected subject.

The disease is transmitted via human contact, when respiratory droplets are
released in the air as an infective subject coughs, sneezes, and (worse even) breathes out or talks. To combat the rapid dissemination of the disease, several governments imposed restrictions on the daily activities of their subjects and self-quarantine for the phase-I infective subjects. Until early May 2020, one-third of the human population stood on lockdown. Updates of the situation are available from a plethora of sources, including Refs. [1].

The principal goal in this paper is to investigate whether a simple compartmental epidemiological model, categorising the human population into seven groups, can account for the dissemination of COVID-19 disease. Excepting the fixation of six of the model parameters from external sources, the only input to this study is the cumulative number of fatalities due to the disease, i.e., information which is reported daily by all sovereign countries. The model is tested on the data from the five countries which have borne the brunt of the death toll, namely more than 70% of the reported fatalities by April 30, 2020; these countries (in descending order of the total number of fatalities) are: the United States (US), Italy, the United Kingdom (UK), Spain, and France. After fixing three of the model parameters from each input dataset, one may predict how the disease (or, more precisely, the current cycle/wave of the disease) will develop (within that country).

The structure of this paper is as follows. The subsequent section introduces the model, starting from the definition of its seven groups. The parameters in the simplified version of the model (short-term application) are introduced in Section 2.2; also given in that section is a parameterisation of the effective transmissibility in terms of the cumulative number of fatalities due to the disease within one country. Section 2.3 deals with the time evolution of the populations in the seven groups, whereas Section 2.4 addresses the selection of the specific input to the model. Section 2 is concluded with details about the optimisation procedure. Section 3.1 discusses the fixation of seven of the model parameters, whereas the subsequent section provides the optimal (fitted) values and uncertainties of the three parameters (Table 1) which are varied to achieve the optimal description of the input data. Also given in that part are details about the description of the input datasets (Figs. 2-4). The final part of Section 3 lists some predictions which are obtained from the results of the optimisation. The conclusions of this study are given in the last section, Section 4.

Unless otherwise stated, the dates in this work refer to the current year, i.e., 2020. Finally, the time unit herein is one day (d).
2 A compartmental epidemiological model for the dissemination of the COVID-19 disease

The first compartmental models in Epidemiology are approximately one century old. A good review of the efforts to model the dissemination of infectious diseases may be found in Ref. [2]. This note will be kept as short as possible, containing only what (in my judgement) is relevant to the model which is put forward in this study in order to account for the dissemination of the COVID-19 disease (and similar diseases). The transfer diagram of this model is displayed in Fig. 1.

2.1 Definitions

At a given time, each subject is categorised into one of the following seven groups:

- The ‘susceptible’ subjects (\(S\)) are those who can be infected.
- The ‘exposed’ subjects (\(E\)) are those who have been infected, but are not yet infective themselves.
- The ‘asymptomatic infective’ subjects (\(I_0\)) are those who have been infected, but - whichever the reason - are not symptomatic.
- The ‘symptomatic phase-I infective’ subjects (\(I_1\)) are infective subjects who are developing weak symptoms.
- The ‘symptomatic phase-II infective’ subjects (\(I_2\)) are infective subjects who are developing strong symptoms (hospitalisation, severe or critical condition).
- The ‘immune’ or ‘unsusceptible’ subjects (\(\bar{S}\)) are those who have recovered with immunity, as well as those who might have been immune to the disease in the first place.
- The ‘deceased’ subjects (\(D\)) are those who did not survive the phase II of the disease.

Evidently, these seven populations depend on time \(t\). Two remarks need to be made. a) At this time, it remains unknown whether the asymptomatic subjects are infectious [3], how much infectious they might be, and for how long; they will be treated here as equally infectious (and for an equally long temporal interval) as if they had been \(I_1\) subjects (who recover from the disease). b) It remains unknown whether (at least in some cases) recovery from the COVID-19 disease induces immunity against the virus; also unknown is for how long such immunity might last.

In this form (to be referred to as ‘simplified version’ henceforth), the model contains no vital dynamics (no births or deaths due to other causes) or the
Fig. 1. The transfer diagram of the compartmental epidemiological model of this work.
effects of vaccination. The inclusion of both effects will be made in Appendix A. The model treats the humans as statistical units, i.e., with no regard to race, gender, age, place of residence, social engagement, etc. Naturally, the model can also be applied to subgroups of the human population.

The discussion will be facilitated if, prior to entering the details, some additional definitions are given. As far as the early development of the disease for one infected subject is concerned, three are the important moments:

- the instant \( t_1 \) at which the subject becomes infected,
- the instant \( t_2 \) at which the subject becomes infective, and
- the instant \( t_3 \) marking the onset of symptoms.

(For some diseases, \( t_2 > t_3 \): an infected subject becomes infective after the onset of symptoms. In the case of the COVID-19 disease, there are indications of pre-symptomatic transmission.) Were the development of such diseases identical for all infected subjects, an infector and a related infectee would follow time-shifted, yet identical, timelines: if \( t_1, t_2, \) and \( t_3 \) were the infector’s timeline characteristics, those of the infectee would be: \( t'_1 = t_1 + \Delta t \), \( t'_2 = t_2 + \Delta t \), and \( t'_3 = t_3 + \Delta t \), where the constant temporal interval \( \Delta t \geq t_2 - t_1 \) (and smaller than the temporal interval during which the infector remains infectious).

However, neither the infection-to-infectiousness (\( t_2 - t_1 \)) nor the incubation (\( t_3 - t_1 \)) interval may be thought of as \( \delta \)-distributed quantities; in case of the COVID-19 disease, broad distributions have been established. To study the dissemination of diseases, three temporal intervals are routinely used in Epidemiology:

- the incubation interval \( t_3 - t_1 \) (defined for one subject),
- the onset-to-onset interval (serial interval) \( t'_3 - t_3 \) (defined for an infector-infectee pair), and
- the infection-to-infection interval (generation interval) \( t'_1 - t_1 \) (defined for an infector-infectee pair).

One would expect that a) these three intervals are positive and b) the serial and generation intervals are equal. In reality, only the incubation and generation intervals are positive; negative estimates for the serial interval have appeared, implying that - on occasion - the infectee develops symptoms before the infector does; in the case of COVID-19, a number of studies [4–6] report on distributions of the serial interval extending considerably to negative values.

A weighted average for the incubation interval may be obtained from Refs. [6–14] as 4.77(43) d. On the other hand, a weighted average for the serial interval \(^1\) may be obtained from Refs. [4–7,11,13,16–18] as 4.35(25) d. Compared

\(^1\) A critical review of the existing literature for the serial interval may be found in Ref. [15], which concludes that the value of about 6.6 d has the best chances
to a ‘paired’ analysis, any difference between the mean incubation and serial intervals might be ‘washed out’ when averaging is performed. However, even after considering the studies which reported results on both intervals, consensus does not seem to emerge \(^2\).

2.2 The model parameters

In its simplified version of Fig. 1, the model contains ten parameters, and applies to the short-term (spanning temporal intervals of - typically - a few months) dissemination of diseases (or recurring cycles of diseases) for which no vaccines are available. To be able to model the dissemination of diseases which develop over longer time scales, the model would need enhancement, see Appendix A.

The parameters in the simplified version of the model are:

- Parameter \(\alpha\) is the rate parameter involved in the exponential decrease of the population of the exposed \(E\), provided that the transmission process ceases. As very few results on the generation interval (which should be linked to the parameter \(\alpha\)) are available at this time, \(\alpha\) will be taken to be the inverse of the average serial interval.
- Parameter \(\beta\) (infection rate). Being the product of the average number of contacts per subject per unit time and the probability of virus transmission when an infective contacts a susceptible subject, this parameter may be thought of as the propellant in the outbreak of the disease.
- Parameters \(\gamma_{1,2}\). These two parameters reflect the rates at which the populations \(I_1\) and \(I_2\), respectively, would diminish, were they not replenished by new infections. The decrease in the \(I_1\) population is due either to the recovery of the subject or to the development of strong symptoms (in which case, the subject enters the phase II of the disease and the \(I_2\) population). The decrease in the \(I_2\) population is due either to the subject’s recovery or to the subject’s death.
- Parameter \(p_0\) is the fraction of the exposed who become asymptomatic infective subjects (\(E \rightarrow I_0\)). The remaining subjects, departing from group \(E\), enter the \(I_1\) population.

\(^2\) Tindale and collaborators concluded that the infection was transmitted (on average) 2.55 d before the symptom onset in Singapore and 2.89 d before the symptom onset in Tianjin, China [11]; a similar conclusion was drawn by Ganyani and collaborators [5]. On the contrary, Zhang and collaborators found no evidence that the average incubation and serial intervals significantly differ [13].
Parameter $p_1$ is the fraction of the symptomatic phase-I infective subjects who enter the phase II of the disease ($I_1 \rightarrow I_2$).

Parameter $p_2$ is the fraction of the recoveries without immunity.

Parameter $p_3$ is the fatality rate, defined here as the fraction of the symptomatic phase-II infective subjects who do not recover ($I_2 \rightarrow D$).

Two remarks are due. a) From the point of view of the infectiousness and the recovery rate, the asymptomatic infective subjects are treated as if they were symptomatic phase-I infective subjects; unlike in Ref. [19], the assumption that the asymptomatic infective subjects are less infectious than the subjects of the other two infective groups $I_1$ and $I_2$ will not be made here. b) The recoveries without immunity involve the same probability ($p_2$) regardless of the type of the recovered subject (i.e., whether that subject originally belonged to the $I_0$, $I_1$, or $I_2$ group).

The most essential factor in the dissemination of a disease is how the transmission compares to the recovery rate. Evidently, if the former is larger, the disease spreads; otherwise, it dies off with time. The aggressiveness of a virus is encoded in the ratio $\beta/\gamma$, identified in Epidemiology as the basic reproduction number $R_0$ (also known as transmissibility). In this study, $R_0$ will be the basic reproduction number, the property associated with the free dissemination of the disease, i.e., in the absence of any mitigation measures or (in general) enforced/spontaneous modifications in social behaviour. On the contrary, the transmissibility of the disease in an environment where restrictions apply (either due to measures imposed on the social activities of the subjects or due to modifications in the behaviour of the humans as the disease spreads) will be the effective transmissibility, a time-dependent quantity, and will be denoted by $R$. The importance of the mitigation measures in controlling the dissemination of the COVID-19 disease has been addressed in Ref. [20].

Under these definitions, it follows that a disease tends to spread if $R > 1$, whereas it tends to wane if $R < 1$. The sole aim of the mitigation measures is to bring $R$ to values below 1, and - desirably - make it as small as possible. The only parameter which pertains to human behaviour (and may therefore be modified) is $\beta$. Isolation and restrictions in movement aim at reducing the number of contacts per subject per unit time, whereas the social distancing aims at reducing the probability of the virus transmission per contact. Either way, $\beta$ is reduced, resulting (under constant $\gamma$) in a reduction in $R$. In this work, $R$ will be identified as the ratio $\beta/\gamma_1$, where $\beta$ may be thought of as the

$\beta$ Several quoted fatality rates in the case of the COVID-19 disease are misleading, because they are based on the number of confirmed (tested COVID-19-positive) cases; therefore, the asymptomatic infective subjects, as well as most of those exhibiting weak symptoms (who do not suspect that they have been infected by the COVID-19 virus and have therefore no reason to subject themselves to testing), hardly contribute.
effective infection rate, as opposed to the constant $\beta_0$ which is a characteristic of each virus.

At the beginning of this section, it was mentioned that the simplified version of the model contains ten parameters, yet eight have been listed thus far. The last two parameters enter the empirical modelling of the effective transmissibility.

The effect of the dissemination of a life-threatening disease is the inevitable increase in the cumulative number of fatalities with increasing time. Mitigation measures aim at disrupting the transmission process of the virus, hence at reducing the number of new infections, hence at reducing the number of new fatalities. Evidently, the reduction in transmissibility may be thought of as due to the imposition of the mitigation measures or to modifications of each subject’s behaviour as a result of the rise in the exposure to danger, intensifying with increasing cumulative number of fatalities. My thesis is that what drives the reduction in transmissibility, the cause or the effect, is of no relevance: the important issue is the association between the reduction in transmissibility and the cumulative number of fatalities within one country. To be able to compare the results across countries, the number of fatalities per country must be normalised to the population of that country; equivalently, one may reduce the number of fatalities to a fixed population, say $n = 100\,000$ subjects, an option which will be followed here. If the cumulative number of fatalities in the initial population $N(0)$ is $D$, then the number of fatalities per $n$ subjects is $d = Dn/N(0)$. The factor (to be applied to $R_0$ in order that $R(t)$, equivalently $\beta(t)$, be extracted) should be 1 at $t = 0$ (in the analysis, $D(0) = 0$) and continue to be equal to that value provided that $D < 1$. One may argue that the reduction in transmissibility commences at the moment of the first fatality, i.e., when $d = d_{\text{min}} = n/N(0)$. The simple form

$$R(d) = R_f + (R_0 - R_f) \exp(-\zeta(d - d_{\text{min}})),$$

applicable for $d > d_{\text{min}}$, was found to work reasonably well. The quantities $R_f$ and $\zeta$ are adjustable (free) parameters; $R_f$ would be the transmissibility if $d$ could reach infinity; $\zeta^{-1}$ is related to the number of fatalities (per 100 000 subjects) which would be required so that the transmissibility drop to the average of $R_0$ and $R_f$. One additional consideration, however inessential as (fortunately) $d \ll n$ in this work, must be taken into account. In reality, $R(n)$ must identically vanish, as the equality $d = n$ implies that there are no susceptible subjects to whom the disease could be transmitted. To be able to take this condition into account, the aforementioned curve $R(d)$ for $R_f \geq 0$ will be followed up to the point $d = d_0$ from where the tangent to the aforementioned curve $R(d)$ passes through the point $(n,0)$; that tangent will then be followed from $d = d_0$ up to the point $(n,0)$. (Of course, $R(d) = 0$ for $d > n$.) If $R_f < 0$, the aforementioned curve $R(d)$ will be followed up to the minimal value between the 0-crossing $d_{\text{min}} - \zeta^{-1} \ln(-R_f/(R_0 - R_f))$ and $n$,.
above which \( R(d) \) will be set to 0. The quantity \( d_0 \) may be obtained iteratively when \( R_f > 0 \) (the convergence is very fast), using the scheme

\[
d_0 = d_{\text{min}} - \frac{1}{\zeta} \ln \left( \frac{R_f}{(R_0 - R_f)(\zeta(n - d_0) - 1)} \right),
\]

whereas analytical solutions are available for \( R_f \leq 0 \). It needs to be emphasized that this correction to Eq. (1) was applied on account of principle and mathematical rigour; to all intents and practical purposes, Eq. (1) suffices.

All model parameters (save for \( R_f \)) are non-negative; furthermore, the probabilities \( p_0, \ldots, p_3 \leq 1 \). In principle, \( R_f > 0 \), though it cannot be excluded that, \( R_f \) being an effective parameter, some data might prefer a negative \( R_f \) value.

### 2.3 Time evolution

The transfer diagram of Fig. 1 leads to the following system of ordinary differential equations (ODEs).

\[
\begin{align*}
\dot{S} &= -\beta SI/N + p_2 \gamma_1 I_0 + (1 - p_1)p_2 \gamma_1 I_1 + (1 - p_3)p_2 \gamma_2 I_2 , \\
\dot{\bar{S}} &= (1 - p_2)\gamma_1 I_0 + (1 - p_1)(1 - p_2)\gamma_1 I_1 + (1 - p_3)(1 - p_2)\gamma_2 I_2 , \\
\dot{E} &= \beta SI/N - \alpha E , \\
\dot{I}_0 &= p_0 \alpha E - \gamma_1 I_0 , \\
\dot{I}_1 &= (1 - p_0) \alpha E - \gamma_1 I_1 , \\
\dot{I}_2 &= p_1 \gamma_1 I_1 - \gamma_2 I_2 , \text{ and} \\
\dot{D} &= p_3 \gamma_2 I_2 ,
\end{align*}
\]

where the dots indicate time derivatives, \( I = I_0 + I_1 + I_2 \) is the total number of infective subjects, and \( N = S + \bar{S} + E + I \) is the total number of subjects who are alive at a given time. For fixed parameters, the time evolution of the seven populations may be obtained via standard methods. The fourth-order Runge-Kutta method with a constant increment of \( 10^{-4} \) d (i.e., 8.64 s) was used, see Ref. [21], pp. 907–910.

### 2.4 Data

To fix the model parameters and be able to make reliable predictions, one needs - in addition to a successful modelling scheme - reliable (and accurate) relevant experimental data. At first, I thought that the number of the new infections in each country could be used as input, but this option was abandoned, as it gradually became clearer that the confirmed cases represent a fraction of
the true amount of the infective subjects $I$; the $I_0$ subjects will not visit a doctor (let alone take any test), and the same goes for many of those who belong to the $I_1$ group: weak symptoms point to common cold or influenza. I therefore came to disregard the number of new infections as providing credible information. For the same reason, I found the recovery rates equally unreliable.

There are two additional reasons why the new infections are not fit for use.

- During the outbreak of the disease, the number of tests, performed daily within one country, generally increased with time. In an environment where not everyone can be tested, the consequence of an increasing number of tests from day to day is an increasing number of new infections, even for a constant population of infective subjects. As there is little or no information about how many tests are performed in each country on a specific date, infection rates (positive tests normalised to the total number of tests performed) can hardly be estimated. In addition, ‘quantum steps’ in the number of tests from day to day (e.g., due to the availability of a more effective test on a specific date) introduce discontinuities in the distribution of the new infections and reduce the reliability of these data further. One may argue that, unless reliable tests are made on random samples of the population in each country (in accordance with the principles of Sampling Theory), the fraction of the infective subjects (in one country, at one time) will remain unknown.

- New infections refer to the time when tests are made and turn out positive, not to the time when the infections truly occur. An infected subject will show the first symptoms after the (broadly-distributed) incubation interval elapses, and might wait for a few additional days (during the phase I of the disease) before seeking medical consultation; it is unlikely that any tests are performed within one week of the infection date. As a result, a delay of several days is certainly to be expected between the time instants when new infections truly occur and when they are discovered, hence reported.

To summarise, yesterday’s reported new infections are not ‘new’ at all; they are one to two weeks ‘old’, perhaps even older. As a result, any analysis of new-infection data must investigate ways to account for this delay.

It then dawned on me that, in all probability, the most reliable piece of information in each country is the number of new fatalities or their cumulative number $D$. I decided to make use of the latter and apply the model in the case of the first five countries on the list of the death toll: the US, Italy, the UK, Spain, and France [22]; by mid April, each of these countries had reported over 10 000 fatalities. In the case of France, the onset corresponds to the second fatality $^4$. The input-cutoff date in this study was set to April 30; the

$^4$ The first fatality was a Chinese tourist who was hospitalised on January 28 and passed away on February 14 [23].
relevant data were inspected on May 4 and 28 for verification.

There are two reasons why I avoided using the global data on the fatalities due to the disease.

- The mitigation measures against the dissemination of the disease were taken by sovereign countries, not at the international level.
- The disease reached different parts of the globe at different times. In order to make meaningful use of the global data, one would have to shift each dataset in time. However, even this operation might not be sufficient. To explain quickly why I do not consider the use of the global data (even after the shifting in time) meaningful, I will refer to the cumulative distribution of new infections and fatalities in Greece and in Switzerland, two European countries with comparable population; these two countries reported their first infections with one day of difference (February 26 and 25, respectively) and their first fatalities within one week (March 12 and 5, respectively). By April 30, 2591 subjects had been confirmed as COVID-19-positive in Greece; 29586 in Switzerland. By that time, Greece counted 140 dead; Switzerland 1737. With hindsight, the dissemination of the disease in each country depends on a variety of factors, namely the timing of the mitigation measures, the efficiency of the healthcare system, the availability of tests, the population density, the social behaviour, the level of cross-border labour mobility (which, in my judgement, had the biggest impact in the aforementioned comparison between Greece and Switzerland), etc. Although the same argument also holds for the counties, provinces, departments, states within one country, their differences are expected to be less prominent than those across sovereign countries.

There are some unexplained features in the data, as they are given in Ref. [22], namely the appearance of daily spikes which are well beyond the statistical fluctuation, as the case is for the number of fatalities in France in a few days in April. There is no doubt that the mis-assignment of fatalities is possible (assessed as COVID-19-related, though unrelated in truth; not assessed as COVID-19-related, though related in truth). The situation worsened in May; some reported values of new infections and fatalities became even negative (e.g., see the number of new infections in France on May 26 and in Spain on May 25, and the number of new fatalities in France on May 19 and in Spain on May 25), indicating ‘aggregated’ corrections to the cumulative number of cases, thus circumventing the trouble of applying the appropriate corrections to the past daily data.
2.5 Optimisation

For the optimisation, the MINUIT software package [24] of the CERN library was used. The MINUIT software package is the standard in Particle Physics, and its robustness has been tested and proved during four decades of application. Other of its advantages include that it is freeware, it is downloadable from a safe site, and it is available in two versions: FORTRAN (the version used here) and C/C++.

Each fit involved four minimisation methods: SIMPLEX, MINIMIZE, MIGRAD, and MINOS.

- **SIMPLEX** uses the simplex method of Nelder and Mead.
- **MINIMIZE** minimises the user-defined function, see Eq. (3), by calling MIGRAD, but reverts to SIMPLEX in case that MIGRAD fails to converge.
- **MIGRAD** is the workhorse of the MINUIT software package. It is a variable-metric method, also checking for the positive-definiteness of the Hessian matrix.
- **MINOS** performs a detailed error analysis, separately for each free parameter. Given that it takes into account the non-linearities in the problem, as well as the correlations among the model parameters, MINOS yields reliable estimates for the fitted uncertainties.

For a fixed parameter vector and initial populations $S(0)$, $\bar{S}(0)$, $E(0)$, $I_0(0)$, $I_1(0)$, $I_2(0)$, and $D(0)$, the system of ODEs of Eq. (2) is solved, yielding the seven populations $S(t)$, $\bar{S}(t)$, $E(t)$, $I_0(t)$, $I_1(t)$, $I_2(t)$, and $D(t)$ up to time $t$, representing the sum of two temporal intervals: the first interval is the time required for $D(t)$ to reach the first fatality/fatalities in the input dataset, whereas the second reflects the temporal span of the specific dataset. As the fatalities are reported daily, the following minimisation function has been implemented:

$$\chi^2 = \sum_{i=1}^{M} \frac{(D_{i}^\text{th} - D_{i}^\text{exp})^2}{D_{i}^\text{exp}} , \quad (3)$$

where $D_{i}^\text{th}$ is the fitted value (corresponding to the solution $D(t)$ for the $i$-th day in the dataset), $D_{i}^\text{exp}$ is the corresponding observation (the cumulative number of fatalities on the $i$-th day, as reported in Ref. [22]), and $M$ is the dimension of the $D_{i}^\text{th,exp}$ arrays. Equation (3) assumes that the uncertainty of $D_{i}^\text{exp}$ is of the square-root-of-N type (underlying Poisson distribution). The elements $D_{i}^\text{th}$ depend on the model parameters. The function of Eq. (3) is submitted to minimisation and the free parameters are varied (internally by MINUIT) until the $\chi^2$ minimum is reached. Apart from the important results of each fit (i.e., the minimal $\chi^2$ value, the fitted values and uncertainties of the model parameters, the Hessian matrix), the MINUIT software package also outputs (by default) a full report, containing the important results obtained.
in the intermediate steps of the optimisation. To ascertain the successful termination of the application and the convergence of its methods, that report was (as it always has been) inspected in all fits.

3 Results

In this study, all results are accompanied by $1\sigma$ uncertainties, the standard in Physics, representing a confidence interval (CI) of $\approx 68.27\%$. To transform the results into corresponding to 95% CI, a routinely-used value in several other scientific domains, one must multiply the quoted uncertainties by $\approx 1.96$. If exceeding 1, the Birge factor $\sqrt{\chi^2/NDF}$, which accounts for the fit quality, was applied to the fitted uncertainties; NDF denotes the number of degrees of freedom in each case, i.e., the number of input datapoints minus the number of free parameters in that fit.

3.1 Fixation of the model parameters

As only the cumulative number of fatalities will be fitted to, efforts need to be made to fix as many parameters as possible from external sources; the data cannot determine more than three parameters (and, of course, also the question of which three parameters are varied is relevant).

- Parameter $\alpha$. Using the average serial interval, extracted from Refs. [4–7,11,13,16–18] (see end of Section 2.1), one may obtain: $\alpha = 0.230(13) \text{ d}^{-1}$.
- Under constant $\gamma_1$, the variation of $R_0$ is equivalent to that of the model parameter $\beta$. A compilation of early $R_0$ determinations in the case of the COVID-19 disease may be found in Ref. [25]. In Ref. [26], the reported $R_0$ range ($1.4 - 3.8$) corresponded to 90% CI. A similar result was extracted in Ref. [7]: $R_0$ was restricted in the $1.4 - 3.9$ interval with 95% confidence. In Ref. [27], Tang and collaborators extracted a large $R_0$ value after making use of an elaborate compartmental model bearing similarities to the one employed herein; the average $R_0$ result was 6.47, accompanied by the range from 5.71 to 7.23 with 95% confidence. In Ref. [11], two values appear: one for Singapore (average value: 1.97, ranging from 1.45 to 2.48 with 95% confidence), the other for Tianjin (average value: 1.87, ranging from 1.65 to 2.09 with 95% confidence). A more accurate result was obtained in Ref. [18], the average value 1.94 being accompanied by a $1\sigma$ uncertainty well below 0.1. Although an $R_0$ value was not explicitly reported in Ref. [28], one may obtain $R_0 \approx 3.42$ from the authors’ Fig. 2, along with an estimated $1\sigma$ uncertainty of $\approx 0.07$, i.e., a value which appears to be compatible with the effective transmissibility values, extracted in Ref. [20] using data from
Wuhan, China, before January 23 (see Fig. 4 therein). Finally, assuming a serial interval between 6 and 9 d, a broader $R_0$ distribution was favoured in Ref. [14], the $R_0$ range extending between 3.8 and 8.9 with 95% confidence. With such an abundance of $R_0$ results, one might have expected that the fixation of this parameter would be straightforward. Unfortunately however, the minimal χ$^2$ value of the reproduction of these $R_0$ results by one constant is about 413.77 for seven degrees of freedom, or 59.11 per degree of freedom, enormous by all standards; one can hardly believe that the aforementioned studies report on the same quantity. Undoubtedly, the $R_0$ results are model-dependent, hence $R_0$ must be treated as a free parameter.

In the optimisation, the (unweighted) average of 3.3 of the values reported in Refs. [7,11,14,18,26–29] will be used as initial guess for $R_0$, and the square root of the unbiased variance of the same values (1.8) as a generous initial guess for the $R_0$ uncertainty.

• Parameters $\gamma_1,2$. A ballpark estimate of the values of these two parameters was contained in the WHO Director-General’s opening remarks at a briefing on February 24 [30]: “for people with mild disease, recovery time is about two weeks, while people with severe or critical disease recover within three to six weeks.”

To obtain the recovery interval in the case of weak symptoms, four estimates for the time between the onset of the illness and hospitalisation have been used; the hospitalisation was taken as indication that the phase I of the disease was completed without obvious recovery. Of the four estimates,

- two came from Ref. [7]: average value 12.5 d, ranging from 10.3 to 14.8 d with 95% confidence (data before January 1), and average value 9.1 d, ranging from 8.6 to 9.7 d with 95% confidence (data between January 1 and 11);
- one from Ref. [13]: average value 4.4 d, entire distribution from 1310 cases ranging from 0.0 to 14.0 d with 95% confidence (data between December 24 and 27, 2019); and
- one from Ref. [14]: average value 5.5 d, ranging from 4.6 to 6.6 d with 95% confidence (data before January 18).

One thus obtains a recovery interval for the phase I of the disease, $T_1 = 4.98(90) \text{ d}$, and from that result: $\gamma_1 = 0.201(36) \text{ d}^{-1}$.

To extract an estimate for $\gamma_2$, five results for the time between the onset of the illness and the conclusion of the hospitalisation, i.e., recovery or death $^5$ of the subject, were used:

- one from Ref. [9]: average value 15.0 d, ranging from 12.8 to 17.5 d with 95% confidence (data from hospitalisation to death);
- two from Ref. [31]: average value 18.0 d, entire distribution from 54 cases ranging from 15.0 to 22.0 d with 50% confidence (data from hospitalisation to death), and average value 22.0 d, entire distribution from 137 cases

---

$^5$ As the phase II of the disease is regulated by one rate parameter ($\gamma_2$), it is of no relevance whether that phase concludes with the subject’s recovery or death.
ranging from 18.0 to 25.0 d with 50% confidence (data from hospitalisation to recovery);
- one from Ref. [18]: average value 20.0 d, ranging from 17.0 to 24.0 d with 95% confidence (data from hospitalisation to death); and
- one from Ref. [14]: average value 16.1 d, ranging from 13.1 to 20.2 d with 95% confidence (data from hospitalisation to death).
The weighted average of \( T_t = 20.2(1.2) \) d is thus extracted. To be able to obtain \( \gamma_2 \), one must subtract from this estimate the recovery interval of the phase I, in which case the characteristic time scale for the development of the phase II of the disease would be 15.2(1.5) d, which finally yields \( \gamma_2 = 0.0658(66) \) d\(^{-1}\).

- Parameter \( p_0 \). To the best of my knowledge, Mizumoto, Kagaya, Zarebski, and Chowell [3] were the first to report on \( p_0 \); their result came from an analysis of data acquired on board of the Diamond Princess cruise ship. In their work, the number of the true asymptomatic was inferred from the time evolution of the ratio of the confirmed subjects who had developed symptoms (by a given time) to those who had not; their result was a true asymptomatic population of 113.3 out of 634 confirmed cases, resulting in \( p_0 = 17.9(1.2)\% \). Very recently, the results of an analysis of five studies of the fraction of the asymptomatic subjects appeared [32]: the authors came up with a total of 65 asymptomatic subjects out of 413 confirmed cases, yielding \( p_0 = 15.7(1.8)\% \). Although the two \( p_0 \) results agree within the uncertainties, the estimate of Ref. [3] was not used in Ref. [32] on account of principle (as aforementioned, the true asymptomatic population is inferred in Ref. [3], not established via medical examination). I will extract a \( p_0 \) estimate from all six studies: summing up the entries of Refs. [3,32], one obtains 178.3(10.7) expected true asymptomatic subjects in a sample of 1047 confirmed cases, yielding \( p_0 = 17.0(1.0)\% \).

- Parameter \( p_1 \). According to Ref. [33], 8255 of 44415 confirmed cases exhibited strong symptoms; this corresponds to 18.59(18)\% of the confirmed cases. A \( p_1 \) result was also obtained in Ref. [10]: 173 out of 1099 confirmed cases exhibited strong symptoms; their \( p_1 \) value (15.7(1.1)\%) is somewhat lower than that of Ref. [33]. By summing up the corresponding entries in these two studies, one obtains \( p_1 = 18.52(18)\% \).

- Parameter \( p_2 \). The optimal value of this parameter is the least known, but (owing to the shortness of the follow-up time - the outstanding majority of the originally susceptible subjects remain unexposed) its impact on the results is deemed minor. According to a recent scientific communication by the WHO [34], “there is currently no evidence that people who have recovered from COVID-19 and have antibodies are protected from a second infection.” Given the expected near insensitivity of the main results of this study to \( p_2 \), the parameter was originally fixed to 1 (no recovery with immunity). However, I decided to opt for \( p_2 = 0.90(5) \), allowing for a small fraction of
recoveries with immunity. Although the odds are not in favour \(^6\), knowing more about \(p_2\) might be helpful in fighting the long-term development of the disease (i.e., potential recurrent cycles of the pandemia).

- **Parameter \(p_3\).** According to Ref. \([33]\), 1 023 out of 44 672 confirmed cases resulted in the subject’s death. As 8 255 out of 44 415 confirmed cases developed strong symptoms, the probability \(p_3\) is \(1023 \cdot 44 \, 415 / (8 \, 255 \cdot 44 \, 672) = 12.32(40)\%\).

- **Parameters \(R_f\) and \(\zeta\) will be varied.** After analysing the results of ten fits to the five datasets of this work, the initial guesses for the average value and uncertainty of the parameter \(R_f\) were fixed to 0.22 and 0.20, respectively; of the parameter \(\zeta\) to 0.78 and 0.40, respectively.

One last remark is due. In Ref. \([35]\), a simple compartmental model with three groups (SIR) was proposed for the dissemination of the COVID-19 disease. Given the two recovery rates of this work, the recovery rate \(\gamma\) of Ref. \([35]\) may be thought as an effective one, related to the quantities \(\gamma_{1,2}\) (hence \(T_1\) and \(T_2\)) of this work. To obtain an effective recovery rate herein, one must first obtain an effective recovery time, e.g., \(T_{\text{eff}} = (1 - p_1)T_1 + p_1T_2\); using the average values and uncertainties of \(T_1\), \(T_2\), and \(p_1\), as detailed above, one extracts: \(T_{\text{eff}} = 7.80(77)\) d. The suggested value in Ref. \([35]\), namely 8.05 d, is in good agreement with the \(T_{\text{eff}}\) result of this work.

In summary, all the model parameters can be and have been fixed from external sources, save for those three (to be specific, \(R_0\), \(R_f\), and \(\zeta\)) which determine the effective transmissibility.

### 3.2 Data description, optimal values of the free parameters

Each call to a MINUIT method generates a growth scenario; in each such case, the initial populations \(S, I_0, I_1, I_2,\) and \(D\) were set to 0, and the number of exposed subjects \(E(0)\) was set to \(10^{-7}N(0);\) of course, \(S(0) = (1 - 10^{-7})N(0).\) (The populations \(N(0)\) of the five countries were fixed to estimates obtained in 2019 or 2020.) Therefore, the disease is assumed to start spreading (at \(t = 0\)) from \(\approx 33\) exposed subjects in the US, from 6 in Italy, etc. Either these subjects became infected in their respective countries (e.g., via contacts with infective tourists) or after a trip abroad; the exact details of the exposures are irrelevant. The system of ODEs of Eq.(2) is solved, yielding \(S(t), E(t), I_0(t), I_1(t), I_2(t), S(t),\) and \(D(t)\) at \(t > 0;\) after the first fatality, the effective transmissibility \(R(d)\) of Eq. (1) is used in the calculation.

\(^6\) Belgium has suffered the highest number of infections (and fatalities) per capita throughout the world, about 0.42% (48 519 infections in a population of 11 515 793, by the input-cutoff date). Assuming recovery without immunity, the probability of two independent infections for the same subject is \(\approx 1.8 \cdot 10^{-5}.\)
The important results of the fits to the five datasets of this study are given in Table 1 (upper part), whereas Figs. 2-4 show the time dependence of the normalised residuals of the fits to the five datasets (given the range of the input data, plots of input and fitted values are not particularly revealing to the naked eye, e.g., see Fig. 5 for the data from the US). As the reduced $\chi^2$ values of Table 1 and Figs. 2-4 demonstrate, the quality of the fits is poor in the pure statistical sense. A few remarks on the five datasets follow.

- Regarding the data from the US, an undulating behaviour is noticeable in the reported number of new fatalities (the same goes for the corresponding data from the UK), with typically $3 - 5$ d of systematically more reported fatalities, followed by $2 - 3$ d of fewer incidents.
- The dataset from Italy is best described with the model.
- The data from Spain pose some questions; the transmission of the virus appears to have been faster there: the number of fatalities rises more sharply with time (than in the other four countries) and approaches saturation faster.
- There is considerable fluctuation in the data from France; that dataset is worst described with the model. The data in the first half of April contain several spikes. The result of these fluctuations on the data description is an unavoidable rise in the $\chi^2$ values of the fits.

There are established ways to smooth ‘noisy’ data (e.g., LOESS, LOWESS, the Savitzky-Golay filter, the application of running-average windows, etc.). However, I decided to avoid applying any kind of smoothing algorithm and to continue instead to use the original values, as they appear in Ref. [22].

The analysis was repeated after imposing a lower cut on the cumulative number of fatalities; the entries below 100 fatalities were ignored and the fits were repeated. This way, the relative uncertainty in each input datapoint does not exceed 10%. It was found that this cut has no sizeable impact on the results, see Table 1, lower part. Therefore, the low-N fluctuations cannot be blamed for the general poorness of the quality of the fits.

To be able to include the effects of the variation of the parameters $\alpha$, $\gamma_{1,2}$, and $p_{0,\ldots,3}$ in the results for the free parameters, the following procedure was put forward. One hundred combinations of random, normally-distributed, uncorrelated values for these parameters were generated, using the results for the central values and the uncertainties according to Section 3.1. Each such combination was used in one fit to the data from one country; as a result, twenty fits per country were performed. The important results (i.e., a country identifier, the minimal $\chi^2$, the NDF, the current values of the seven fixed parameters, as well as the results for the fitted values and uncertainties of the free parameters) were stored in binary files for later processing.
Table 1

The results of the fits of the model to the five datasets used as input (upper part: results from the analysis of the entire datasets; lower part: accepted in the analysis were only the entries exceeding 99 fatalities). The countries are listed in descending order of the fatalities reported by the input-cutoff date in this study (April 30). The first column identifies the country. The second column represents the cumulative number of fatalities \( D \), whereas the adjacent column gives the number of fatalities per 100 000 subjects \( d \) (see end of Section 2.2) in that country. The last four columns contain the reduced \( \chi^2 \) values of the each fit (\( \chi^2 \) per degree of freedom), and the fitted values and uncertainties of the free parameters \( R_0 \), \( R_f \), and \( \zeta \). (The fitted uncertainties of the parameters in the MINUIT output represent standard errors of the means.) In each fit, the remaining model parameters were fixed to the corresponding central values as detailed in Section 3.1. For the fits to the data from France, \( R_f \) was explicitly set to 0.

| Country | \( D \) | \( d \) | \( \chi^2/\text{NDF} \) | \( R_0 \) | \( R_f \) | \( \zeta \) |
|---------|-------|-------|-----------------|--------|--------|--------|
| **No cut** | | | | | | |
| US | 63 856 | 19.45 | 3.37 | 4.977(14) | 0.450(12) | 1.462(14) |
| Italy | 27 967 | 46.37 | 2.78 | 4.900(15) | 0.3285(88) | 0.6759(60) |
| UK | 26 771 | 39.44 | 3.54 | 5.055(83) | 0.3028(75) | 0.636(21) |
| Spain | 24 543 | 52.21 | 3.04 | 6.776(27) | 0.033(16) | 0.6867(75) |
| France | 24 376 | 36.34 | 9.82 | 4.429(96) | Fixed to 0 | 0.416(17) |
| **\( D \geq 100 \)** | | | | | | |
| US | 63 856 | 19.45 | 3.41 | 5.068(14) | 0.461(12) | 1.532(15) |
| Italy | 27 967 | 46.37 | 2.45 | 4.592(13) | 0.3076(86) | 0.5850(50) |
| UK | 26 771 | 39.44 | 2.73 | 4.701(17) | 0.247(18) | 0.5270(72) |
| Spain | 24 543 | 52.21 | 3.33 | 6.510(27) | 0.018(16) | 0.6323(72) |
| France | 24 376 | 36.34 | 13.26 | 4.41(13) | Fixed to 0 | 0.412(23) |

The parameter \( R_f \) was fixed to 0 in the fits to the data from Spain and France; the three-parameter fits occasionally fail as the Hessian matrix either cannot be evaluated or does not come out as expected (i.e., positive definite). After this fixation, no problems were found in the fits. The twenty \( R_0 \) values and fitted uncertainties for each country were analysed further; to avoid the introduction of bias into the results due to any small fitted uncertainties, a median uncertainty was evaluated (per country) and replaced those of the fitted uncertainties (in the results of that country) which were short of that median value. A weighted average was next extracted for each country, along with the rms (root-mean-square) of the \( R_0 \) distribution, see Table 2.
Fig. 2. Description of the data with the compartmental epidemiological model of Fig. 1, for the central values of the fixed parameters as detailed in Section 3.1, and the fitted values of the free parameters from Table 1. The quantity \( r_i = (D_i^{th} - D_i^{exp})/\sqrt{D_i^{exp}} \) is the normalised residual of the \( i \)-th datapoint. The horizontal axis contains the number of days since the first fatality in each country. The plots correspond to the data for the US (upper part of the figure) and Italy (lower part of the figure). The last datapoint in each plot represents the entry on April 30. The horizontal lines have been included for eye guidance; the solid straight line corresponds to the ideal data description (\( r = 0 \)), whereas the two dashed lines delineate the statistical expectation \( |r| = 1 \).

The five average \( R_0 \) values of Table 2 may be thought of as ‘independent observations’. The grand mean was obtained from these values and the standard error of the means was assigned to the grand mean as final uncertainty. The main result of this work is

\[
R_0 = 4.91(34)
\]  

This result lies in between the values reported by Cao and collaborators [29], and by Tang and collaborators [27]. It agrees better with the former result (even though the \( R_0 \) value of Ref. [29] is not accompanied by an uncertainty). The difference to the result of Ref. [27], the largest of the reported \( R_0 \) values for the COVID-19 virus, is \( \approx 3\sigma \). The \( R_0 \) result of this work provides support for the large-\( R_0 \) thesis in the case of the COVID-19 disease.

It must be mentioned that the scheme used in the empirical modelling of the
Fig. 3. Same as Fig. 2 for the data from the UK (upper part) and Spain (lower part).

Fig. 4. Same as Fig. 2 for the data from France. The horizontal axis contains the number of days since the second fatality, see Section 2.4.
Fig. 5. Comparison between input and fitted values for the cumulative number of fatalities in the US. Although the visual inspection of this plot leaves a positive impression, the reduced $\chi^2$ of the fit is equal to 3.37 (see Table 1), indicating a poor data description in the pure statistical sense.

Table 2

Weighted averages and rms values per country for the model parameter $R_0$, obtained from 100 fits (in total) taking account of the effects of the variation of the parameters $\alpha$, $\gamma_{1,2}$, and $p_0,\ldots,3$ according to Section 3.1. Contained in the second column is the range of the $\chi^2$/NDF values of the relevant fits.

| Country | $\chi^2$/NDF | $R_0$     |
|---------|--------------|-----------|
| USA     | 3.35 – 3.42  | 4.99(67)  |
| Italy   | 2.75 – 2.87  | 5.01(90)  |
| UK      | 3.46 – 3.65  | 4.90(69)  |
| Spain   | 2.58 – 5.56  | 6.5(1.2)  |
| France  | 8.04 – 15.93 | 4.35(63)  |

effective transmissibility might have an impact on the estimate for $R_0$. The reliable determination of the effective transmissibility in the dissemination of the COVID-19 disease is an interesting subject, which is surely worth additional investigation. One interesting transmissibility-reduction scheme, fine-tuned to the dissemination of the disease in Wuhan, was introduced in Refs. [27,36].
That scheme quantifies the impact of each of the mitigation measures and appears to be generally applicable (after its parameters have been appropriately fixed, separately for each country).

To provide estimates for the effective transmissibility, other methods have been put forward, e.g., see Ref. [37] for a review. One method, which can easily be implemented and requires only the time series of the new infections in each country, was introduced in Ref. [38]; I have already expressed my scepticism about the reliability of the new-infection time series. Within the framework of that model, the effective transmissibility at time $t$ is shown to follow the Gamma distribution with parameters $a$ and $b$, which may be obtained from the new-infection data between times $t - \delta t$ and $t$, where $\delta t$ is linked to the distribution of the serial interval. To suppress the fluctuation in the extracted values, a user-defined window may be applied to the input data; reasonable results for the COVID-19 disease may be obtained in this approach with typical windows of a few days. The result of the application of the method in the case of the five countries of this work was not satisfactory: the five new-infection time series suggest a power fall-off of the effective transmissibility, which had been tried (before the scheme of Section 2.2 was implemented), but yielded an inferior description of the five datasets compared to Eq. (1).

The most probable temporal interval between the first exposures and the first fatality in each country may also be derived from the data. The results are:

- 14 – 16 d for the US (most likely exposures between February 13 and 16; result of the fit of Table 1, upper part: February 14-15);
- 20 – 22 d for Italy (most likely exposures between January 30 and February 2; result of the fit of Table 1, upper part: January 31-February 1);
- 19 – 21 d for the UK (most likely exposures between February 13 and 16; result of the fit of Table 1, upper part: February 14-15);
- 18 – 19 d for Spain (most likely exposures between February 13 and 15; result of the fit of Table 1, upper part: February 13-14); and
- 21 – 22 d for France (most likely exposures between February 4 and 6; result of the fit of Table 1, upper part: February 5-6).

### 3.3 Predictions

The results of the optimisation may be used in order to predict the time evolution of the seven populations of the model. For the sake of example, one obtains Fig. 6 for the time evolution of the groups $E$, $I$, $I_2$, and $D$ in the US. For this plot, the parameters $\alpha$, $\gamma_{1,2}$, and $p_0, ..., 3$ were fixed to their central values as detailed in Section 3.1. The fitted values of $R_0$, $R_f$, and $\zeta$ for the US were given in Table 1, upper part. An estimate for the total number of
fatalities due to the virus (in fact, for the number of fatalities after this cycle of the pandemic is over) may be obtained by letting the application run for an adequately long follow-up time (representing infinity); running the software for 200 d (up to September 1) yielded the result: $D_\infty \approx 137,226$.

At this time, meaningful uncertainties cannot be assigned to the model predictions; the procedure to obtain these uncertainties is straightforward, but has not yet been implemented. However, working uncertainties may be obtained indirectly, after using empirical models in the optimisation, e.g., models based on the log-normal, the Weibull, or the Gamma distribution; such models yield a relative uncertainty in the cumulative number of fatalities $D_\infty$ around 5%.

It would be interesting to investigate how the model predictions compare with some data which had not entered the optimisation. Selected in this respect was May 31, i.e., one month after the input-cutoff date for the inclusion of data in the five databases of this work. The model predictions for the five countries, along with the actual data on May 31 (copied from Ref. [22] on June 1), are given in Table 3. In the worst case, the difference between the predicted and observed values remains below 2.6%.

It must be emphasised that predictions make sense if the collective behaviour continues to be shaped in accordance to the scheme used in the empirical
Table 3

The model predictions for the cumulative number of fatalities by May 31, 2020, for the five countries used herein. The observed values were copied from Ref. [22] on June 1. The second column contains the number of days $N_r$ between the expected first exposures (generally different for the five countries) and May 31. It must be mentioned again that the predictions were derived from input data before May 1, hence no data from May were involved in any way in the database used in the optimisation. RSD denotes the relative symmetrised difference (difference between prediction and observation, normalised to their average).

| Country | $N_r$ (d) | Predicted $D$ | Observed $D$ | RSD (%) |
|---------|-----------|---------------|---------------|---------|
| USA     | 107       | 104 850       | 106 195       | −1.27   |
| Italy   | 121       | 33 265        | 33 415        | −0.45   |
| UK      | 107       | 37 657        | 38 489        | −2.19   |
| Spain   | 108       | 26 817        | 27 127        | −1.15   |
| France  | 116       | 29 544        | 28 802        | 2.54    |

modelling of the effective transmissibility. If the collective behaviour is modified, be that due to the relaxation of the mitigation measures or to re-adjusted norms following the long-term exposure of the general public to a lasting phenomenon (habituation), any predictions are likely to fail.

4 Conclusions and discussion

This work introduces a compartmental epidemiological model based on seven groups and tailored to the characteristics of diseases similar to the COVID-19 disease. In its simplified version, the model contains ten parameters, four of which relate to the physical characteristics of the virus, and four are transition probabilities between the groups; the last two parameters enable the empirical modelling of the effective transmissibility within one country, which is linked in this study to the cumulative number of fatalities in that country.

The novel part in this work is that it uses only the cumulative number of fatalities due to the disease in each country, i.e., data from the public domain. Given that, due to the unavailability of a fast and reliable test, the number of infected subjects remains uncertain, the number of fatalities may be regarded (in my judgement) as the most reliable piece of information regarding this disease. Of course, ‘being the most reliable’ is not synonymous to ‘being reliable’. Although I have not seen scientific studies on the reliability of the reported number of fatalities, several experts (and non-experts) have expressed their
scepticism in newspaper and journal articles, in interviews, and in blogs. In some cases, it has been suggested that the true numbers of fatalities may be as much as 60% higher than those reported [39].

Fits of the model to the data from five countries, namely from those which have been hit most severely by the disease (regarding the total number of fatalities), have been performed following a transmissibility-reduction scheme based on the cumulative number of fatalities. An estimate for the basic reproduction number $R_0 = 4.91(34)$, the most important measure of the aggressiveness of a virus, for the free dissemination of the COVID-19 disease (no mitigation measures, no modification in the collective behaviour as a result of the rising death toll) has been obtained, see Eq. (4). This result disagrees with several early determinations, and points to a more aggressive virus (than those early determinations had suggested); this estimate places the COVID-19 disease at equal level with poliomyelitis, rubella, pertussis, smallpox, and distances it from common cold and influenza.

Provided that the future behaviour of the susceptible subjects is in accordance with their past behaviour (e.g., regarding social distancing and self-isolation in suspected cases), predictions for the time evolution of the seven populations of the model may be obtained from the results of the fits.

Last but not least, the reliability of the results extracted herein relies on the validity of a number of assumptions.

- No significant contributions have been left out of the transfer diagram of the model (see Fig. 1).
- The association between the reduction in transmissibility and the cumulative number of fatalities in each country, as explained in Section 2.2, holds. It might be that the scheme used in the empirical modelling of the effective transmissibility has an impact on the extracted estimate for the nominal transmissibility $R_0$ of Eq. (4).
- The average values of the model parameters are not sizeably different to the results detailed in Section 3.1.
- The correctness of the quoted uncertainty in the nominal transmissibility $R_0$ rests upon the correctness of the uncertainties of the parameters $\alpha$, $\gamma_1, 2$, and $p_{0,\ldots,3}$ as detailed in Section 3.1.

Acknowledgements

I am indebted to Kenneth McIntosh for answering a few questions regarding the asymptomatic infective subjects in the case of the COVID-19 virus; to Megan Murray for answering a question regarding the extraction of the
effective transmissibility from the data; and to Marco Ajelli for answering a question regarding Ref. [13].

Figure 1 has been created with CaRMetal [40]. The remaining figures have been created with MATLAB® (The MathWorks, Inc., Natick, Massachusetts, United States).

I have no affiliations with or involvement in any organisation, institution, company, or firm with/without financial interest in the subject matter of this work.

References

[1] https://www.who.int; https://coronavirus.jhu.edu; https://en.wikipedia.org/wiki/Coronavirus_disease_2019; https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention; https://ourworldindata.org/coronavirus

[2] H.W. Hethcote, ‘The Mathematics of infectious diseases’, SIAM Rev. 42 (2000) 599–653; available from https://www.jstor.org/stable/2653135

[3] K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, ‘Estimating the asymptomatic proportion of Coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020’, Euro. Surveill. 25 (2020) 2000180. DOI: 10.2807/1560-7917.ES.2020.25.10.2000180

[4] Z. Du et al., ‘Serial interval of COVID-19 among publicly reported confirmed cases’, Emerg. Infect. Dis. 26 (2020). DOI:10.3201/eid2606.200357

[5] T. Ganyani et al., ‘Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020’, Euro. Surveill. 25 (2020) 2000257. DOI:10.2807/1560-7917.ES.2020.25.17.2000257

[6] C. You et al., ‘Estimation of the time-varying reproduction number of COVID-19 outbreak in China’, Int. J. Hyg. Envir. Heal. (2020). DOI: https://doi.org/10.1016/j.ijheh.2020.113555

[7] Q. Li et al., ‘Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia’, N. Engl. J. Med. 382 (2020) 1199–1207. DOI: 10.1056/NEJMoa2001316

[8] J.A. Backer, D. Klinkenberg, J. Wallinga, ‘Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020’, Euro. Surveill. 25 (2020) 2000062. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062
[9] N.M. Linton et al., ‘Incubation period and other epidemiological characteristics of 2019 novel Coronavirus infections with right truncation: A statistical analysis of publicly available case data’, J. Clin. Med. 9 (2020) 538. DOI: 10.3390/jcm9020538

[10] W. Guan et al., ‘Clinical characteristics of Coronavirus disease 2019 in China’, N. Engl. J. Med. 382 (2020) 1708–1720. DOI: 10.1056/NEJMoa2002032

[11] L.C. Tindale et al., ‘Transmission interval estimates suggest pre-symptomatic spread of COVID-19’, medRxiv: 2020.03.03.20029983. DOI: 10.1101/2020.03.03.20029983

[12] S.A. Lauer et al., ‘The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application’, Ann. Intern. Med. 172 (2020) 577–582. DOI: 10.7326/M20-0504

[13] J. Zhang et al., ‘Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study’, Lancet Inf. Dis. 2020. Published online April 2, 2020. DOI: 10.1016/S1473-3099(20)30230-9

[14] S. Sanche et al., ‘High contagiousness and rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2’, Emerg. Infect. Dis. 26 (2020). DOI: 10.3201/eid2607.200282

[15] J.M. Griffin et al., ‘A rapid review of available evidence on the serial interval and generation time of COVID-19’, medRxiv: 2020.05.08.20095075. DOI: 10.1101/2020.05.08.20095075

[16] S. Zhao et al., ‘Estimating the serial interval of the novel coronavirus disease (COVID-19): A statistical analysis using the public data in Hong Kong from January 16 to February 15’, medRxiv: 2020.02.21.20026559. DOI: 10.1101/2020.02.21.20026559

[17] H. Nishiura, N.M. Linton, A.R. Akhmetzhanov, ‘Serial interval of novel coronavirus (COVID-19) infections’, Int. J. Infect. Dis. 93 (2020) 284–286. DOI: 10.1016/j.ijid.2020.02.060

[18] J.T. Wu et al., ‘Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China’, Nat. Med. 26 (2020) 506–510. DOI: 10.1038/s41591-020-0822-7

[19] N.M. Ferguson et al.(Imperial College COVID-19 Response Team), ‘Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand’. DOI: 10.25561/77482

[20] A. Pan et al., ‘Association of public health interventions with the Epidemiology of the COVID-19 outbreak in Wuhan, China’, JAMA. Published online April 10, 2020. DOI: 10.1001/jama.2020.6130

[21] W.H. Press, S.A. Teukolsky, W.T. Vetterling, B.P. Flannery, ‘Numerical Recipes: The Art of Scientific Computing’ (3rd edn.), Cambridge University Press, 2007.
[22] Available from https://www.worldometers.info/coronavirus

[23] Available from https://en.wikipedia.org/wiki/2020-coronavirus_pandemic_in_France

[24] F. James, ‘MINUIT - Function Minimization and Error Analysis’, CERN Program Library Long Writeup D506, CERN, 1998.

[25] Y. Liu, A.A. Gayle, A. Wilder-Smith, J. Rocklöv, ‘The reproductive number of COVID-19 is higher compared to SARS coronavirus’, J. Travel Med. 27 (2020). DOI: 10.1093/jtm/taaa021

[26] J. Riou, C.L. Althaus, ‘Pattern of early human-to-human transmission of Wuhan 2019 novel Coronavirus (2019-nCoV), December 2019 to January 2020’, Euro. Surveill. 25 (2020) 2000058. DOI: 10.2807/1560-7917.ES.2020.25.4.2000058

[27] B. Tang, ‘Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions’, J. Clin. Med. 9 (2020) 462. DOI: 10.3390/jcm9020462

[28] J. Hwang, H. Park, S.-H. Kim, J. Jung, N. Kim, ‘Basic and effective reproduction numbers of COVID-19 cases in South Korea excluding Sicheonji cases’, medRxiv: 2020.03.19.20039347. DOI: 10.1101/2020.03.19.20039347

[29] Z. Cao et al., ‘Estimating the effective reproduction number of the 2019-nCoV in China’, medRxiv: 2020.01.27.20018952. DOI 10.1101/2020.01.27.20018952

[30] Available from https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020

[31] F. Zhou et al., ‘Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study’, Lancet 395 (2020) 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3

[32] O. Byambasuren et al., ‘Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis’, medRxiv: 2020.05.10.20097543. DOI: 10.1101/2020.05.10.20097543

[33] Z. Wu, J.M. McGoogan, ‘Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention’, JAMA 323 (2020) 1239–1242. DOI: 10.1001/jama.2020.2648

[34] https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19

[35] J. Sreevalsan-Nair, R.R. Vangimalla, P.R. Ghogale, ‘Analysis of clinical recovery-period and recovery rate estimation of the first 1000 COVID-19 patients in Singapore’, medRxiv: 2020.04.17.20069724. DOI: 10.1101/2020.04.17.20069724
[36] B. Tang et al., ‘An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)’, Infect. Dis. Model. 5 (2020) 248–255. DOI: 10.1016/j.idm.2020.02.001

[37] K.V. Parag, C.A. Donnelly, ‘Optimising renewal models for real-time epidemic prediction and estimation’, bioRxiv: 835181. DOI: 10.1101/835181

[38] A. Cori, N.M. Ferguson, C. Fraser, S. Cauchemez, ‘A new framework and software to estimate time-varying reproduction numbers during epidemics’, Am. J. Epidemiol. 178 (2013) 1505–1512. DOI: 10.1093/aje/kwt133

[39] J. Burn-Murdoch, V. Romei, C. Giles, ‘Global coronavirus death toll could be 60% higher than reported’, Financial Times, April 26, 2020, available from https://www.ft.com/content/6bd88b7d-3386-4543-b2e9-0d5c6fac846c

[40] Available from http://carmetal.org/index.php/fr
A The inclusion of vital dynamics

The inclusion of the vital dynamics, as well as of the effects of the vaccination, introduces three additional parameters:

- The birth rate $\lambda$ in the country under investigation.
- The mortality rate $\mu$ in the country under investigation.
- The vaccination rate $\epsilon$.

Discarding passive immunity, the complete version of the model rests upon the following system of ODEs.

\[
\begin{align*}
\dot{S} &= -\beta SI/N + p_2 \gamma_1 I_0 + (1 - p_1)p_2 \gamma_1 I_1 + (1 - p_3)p_2 \gamma_2 I_2 - \epsilon S + \lambda N - \mu S , \\
\dot{S} &= (1 - p_2)\gamma_1 I_0 + (1 - p_1)(1 - p_2)\gamma_1 I_1 + (1 - p_3)(1 - p_2)\gamma_2 I_2 + \epsilon S - \mu S , \\
\dot{E} &= \beta SI/N - (\alpha + \mu)E , \\
\dot{I}_0 &= p_0 \alpha E - (\gamma_1 + \mu)I_0 , \\
\dot{I}_1 &= (1 - p_0)\alpha E - (\gamma_1 + \mu)I_1 , \\
\dot{I}_2 &= p_1 \gamma_1 I_1 - (\gamma_2 + \mu)I_2 , \text{ and} \\
\dot{D} &= p_3 \gamma_2 I_2 + \mu N ,
\end{align*}
\]  

(A.1)

where $I = I_1 + I_2 + I_3$ and $N = S + \bar{S} + E + I$. This model may be used when dealing with diseases which spread over temporal intervals longer than a few months. Of course, a lack of vaccine implies that $\epsilon = 0$. 